Hims & Hers Health, Inc. (HIMS)
| Market Cap | 7.13B |
| Revenue (ttm) | 2.21B |
| Net Income (ttm) | 133.79M |
| Shares Out | 227.65M |
| EPS (ttm) | 0.54 |
| PE Ratio | 58.34 |
| Forward PE | 54.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,131,152 |
| Open | 32.03 |
| Previous Close | 32.20 |
| Day's Range | 30.75 - 32.04 |
| 52-Week Range | 23.97 - 72.98 |
| Beta | 2.37 |
| Analysts | Hold |
| Price Target | 43.82 (+39.91%) |
| Earnings Date | Feb 23, 2026 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $43.82, which is an increase of 39.91% from the latest price.
News
Hims & Hers stock is crashing: will it rebound soon?
Hims & Hers stock has nosedived in the past few months. It has dived by over 56% from its highest point in July last year and is now hovering at its lowest level since April.
Hims & Hers Health: Capitalizing On Healthcare Innovation
Hims & Hers Health remains a speculative buy for aggressive growth investors, driven by its pivot toward precision medicine and AI-enabled healthcare. Recent volatility stems from regulatory risks, th...
Hims & Hers Growth Story Has A Lot To Prove In 2026
Hims & Hers is down 50% from all-time highs amid fading momentum in their compounded GLP-1 offerings, while new growth vectors are yet to translate into revenue acceleration. Sequential revenue decele...
Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth
Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical integratio...
Hims & Hers Health: Under-Appreciated Upside
Hims & Hers Health is aggressively expanding through new product launches, international markets, and strategic acquisitions, supporting a bullish outlook. HIMS targets $6.5 billion in 2030 revenue, l...
Hims & Hers: A Rare GARP Setup After The Market Reset
Hims & Hers is an asset-light platform. Subscriptions, cross-selling, and personalization drive rising ARPU, strong retention, and improving unit economics with structurally low CAC. Growth has normal...
Hims & Hers: Capitalizing On Robust Subscriber/ARPU Growth - Upgraded Buy Rating
HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international expansio...
Hims & Hers Health Is Building A Hormonal Empire
Hims & Hers Health shares are down 30%, but I maintain a Buy rating due to compelling long-term growth levers. HIMS's core business growth is slowing, yet margin expansion, product innovation, and int...
Hims & Hers: A Great Moment To Buy The Dip
Hims & Hers remains a "Buy" as recent catalysts, including renewed GLP-1 partnership talks and share buybacks, support a rebound thesis. HIMS boasts a sticky, high-margin customer base, expanding into...
HIMS Stock On A Losing Spree: Here's Why
Hims & Hers Health (HIMS) stock has experienced a 7-day losing streak, resulting in total losses of 8.7% over this time frame. The company's market capitalization has plummeted by approximately $699 m...
These 5 Stocks Are Set To Dominate 2026
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Euro...
Hims and Hers to offer weight-loss treatments in UK
Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United Kingdom which will include drugs like Novo Nordisk's Wegovy, the company said o...
Hims & Hers Brings Comprehensive Weight Loss Programme to the UK
LONDON--(BUSINESS WIRE)--Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction...
Hims & Hers: The Market's Panic Is Irrational
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification...
A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity
Hims & Hers Health expands into Canada via Livewell acquisition, targeting a large, underserved weight-loss market. Canadian entry leverages local leadership and expertise, aiming to replicate success...
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one month before generic semaglutide ...
Hims & Hers Now Serving Customers in Canada
MONTREAL--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent acqui...
Hims & Hers Continues Major International Expansion With Official Entry Into Canada
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent ...
Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology
SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire You...
GraniteShares Expands YieldBOOST™ Lineup with Two New ETFs Targeting RIOT Platforms and Hims & Hers Health (RTYY and HMYY)
New York, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- GraniteShares, a one of the leading issuer of exchange-traded funds (ETFs), today announced the launch of two new additions to its growing YieldBOOST ™ ...
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product of...
Hims & Hers: The Growth Story Is Outside GLP-1s
Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization ...